knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 17:43:42 - browse：1

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Why patients can’t get everything they want on drug pricing

WSS

Air quality improving but still lags in Black, Hispanic communities

STAT Report: Patient voices and perspectives

The battle over 'scope creep' and who gets to be called 'doctor'

The battle over 'scope creep' and who gets to be called 'doctor'

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

The Readout: Amylyx, Alumis, and Lundbeck drug updates

explore

knowledge

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Biogen says it will cut costs by $700 million, slash 1,000 jobs

ChatGPT in medicine: STAT answers readers' burning questions

CDC marks new Covid

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

With psoriasis trial ahead, Alumis raises $259 million

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UnitedHealth quietly bought dozens of outpatient centers

Hepatitis C has a cure — but many Americans still lack access to it

In his State of the Union, Biden takes clear aim at 'Big Pharma'

knowledge

CDC marks new Covid

Search called off for baby washed away in Pennsylvania flash flood

In his State of the Union, Biden takes clear aim at 'Big Pharma'

The Readout: Amylyx, Alumis, and Lundbeck drug updates

STAT Report: Patient voices and perspectives

Amylyx ALS drug fails large clinical trial

focus

focus

hotspot

leisure time